Ms Kristin Zielinski Duggan > Hogan Lovells US LLP > Washington DC, United States > Lawyer Profile
Hogan Lovells US LLP Offices
COLUMBIA SQUARE
555 THIRTEENTH STREET, NW
WASHINGTON DC 20004
DISTRICT OF COLUMBIA
United States
- Firm Profile
- Go to...
Ms Kristin Zielinski Duggan
Work Department
Medical Device and Technology Regulatory
Position
Counsel
Career
With a background in biology and economics, Kristin Zielinski Duggan provides strategic advice to companies on scientific and U.S. Food and Drug Administration (FDA) regulatory challenges, while always keeping business needs in mind. For over 20 years, she has been counseling cutting-edge companies regarding the development and regulation of medical devices and combination products. Kristin has a wealth of experience with the entire FDA regulatory process from concept through commercialization, and specializes in FDA Advisory Panels.
Kristin previously served as Vice President for Strategic Consulting at a Washington, D.C.-based scientific consulting firm. Throughout her career, she has published and presented on various FDA regulatory issues. She is also an adjunct professor at Georgetown University’s School of Nursing and Health Studies.
Languages
English
Memberships
Member, Regulatory Affairs Professionals Society (RAPS)
Member, Food and Drug Law Institute (FDLI)
Education
J.D., Georgetown University Law Center, 2015; B.A., University of Virginia, 1998
Leisure
Running, boating
Top Tier Firm Rankings
- Transport > Aviation and air travel: litigation and regulation
- Antitrust > Cartel
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Industry focus > Education
- Government > Government relations
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Transport > Rail and road: litigation and regulation
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
- International Trade > Trade remedies and trade policy
Firm Rankings
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- International Trade > CFIUS
- International Trade > Customs, export controls and economic sanctions
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy regulation: oil and gas
- Environment > Environment: litigation
- Environment > Environment: regulatory
- Government > Government contracts
- Healthcare > Health insurers
- Healthcare > Life sciences
- Healthcare > Service providers
- Tax > US taxes: non-contentious
- Insurance > Advice to insurers
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Energy > Energy regulation: electric power
- Finance > Fintech
- Labor and employment > Immigration
- Dispute resolution > International litigation
- Tax > International tax
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Antitrust > Merger control
- M&A/corporate and commercial > Shareholder activism
- Finance > Structured finance: derivatives and structured products
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
- Antitrust > Civil litigation/class actions: defense
- Energy > Energy litigation: oil and gas
- Finance > Project finance
- Energy > Renewable/alternative power
- Finance > Restructuring (including bankruptcy): corporate
- Finance > Project finance
- Dispute resolution > International arbitration
- Finance > Financial services regulation
- Investment fund formation and management > Private equity funds (including venture capital)